Global Covid-19 Treatment Medicine 麻豆原创 Research Report 2024

Publication ID:

PB503244756

Publication Date:

March 25, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

IT Services [2]

Hardware (Computing & Electronics) [3]

Computing & Electronics [4]

Description:

Covid-19 Treatment Medicines are medications use to treat COVID-19, including oral and Injetion Medicine.
The global Covid-19 Treatment Medicine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Covid-19 Treatment Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Covid-19 Treatment Medicine.
Report Scope
The Covid-19 Treatment Medicine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Covid-19 Treatment Medicine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Covid-19 Treatment Medicine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer (Paxlovid)
VEKLURY (Remdesivir)
Lagevrio
GSK (Sotrovimab)
Regeneron (Ronapreve)
Yiling Pharmaceutical
Segment by Type
Oral
Injetion
Segment by Application
Mild-to-Moderate COVID-19
Severe Patient
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Covid-19 Treatment Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Covid-19 Treatment Medicine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Covid-19 Treatment Medicine 麻豆原创 Overview
1.1 Product Overview and Scope of Covid-19 Treatment Medicine
1.2 Covid-19 Treatment Medicine Segment by Type
1.2.1 Global Covid-19 Treatment Medicine 麻豆原创 Value Comparison by Type (2024-2030)
1.2.2 Oral
1.2.3 Injetion
1.3 Covid-19 Treatment Medicine Segment by Application
1.3.1 Global Covid-19 Treatment Medicine 麻豆原创 Value by Application: (2024-2030)
1.3.2 Mild-to-Moderate COVID-19
1.3.3 Severe Patient
1.4 Global Covid-19 Treatment Medicine 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Covid-19 Treatment Medicine Revenue 2019-2030
1.4.2 Global Covid-19 Treatment Medicine Sales 2019-2030
1.4.3 Global Covid-19 Treatment Medicine 麻豆原创 Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Covid-19 Treatment Medicine 麻豆原创 Competition by Manufacturers
2.1 Global Covid-19 Treatment Medicine Sales 麻豆原创 Share by Manufacturers (2019-2024)
2.2 Global Covid-19 Treatment Medicine Revenue 麻豆原创 Share by Manufacturers (2019-2024)
2.3 Global Covid-19 Treatment Medicine Average Price by Manufacturers (2019-2024)
2.4 Global Covid-19 Treatment Medicine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Covid-19 Treatment Medicine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Covid-19 Treatment Medicine, Product Type & Application
2.7 Covid-19 Treatment Medicine 麻豆原创 Competitive Situation and Trends
2.7.1 Covid-19 Treatment Medicine 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Covid-19 Treatment Medicine Players 麻豆原创 Share by Revenue
2.7.3 Global Covid-19 Treatment Medicine 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Covid-19 Treatment Medicine Retrospective 麻豆原创 Scenario by Region
3.1 Global Covid-19 Treatment Medicine 麻豆原创 Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Covid-19 Treatment Medicine Global Covid-19 Treatment Medicine Sales by Region: 2019-2030
3.2.1 Global Covid-19 Treatment Medicine Sales by Region: 2019-2024
3.2.2 Global Covid-19 Treatment Medicine Sales by Region: 2025-2030
3.3 Global Covid-19 Treatment Medicine Global Covid-19 Treatment Medicine Revenue by Region: 2019-2030
3.3.1 Global Covid-19 Treatment Medicine Revenue by Region: 2019-2024
3.3.2 Global Covid-19 Treatment Medicine Revenue by Region: 2025-2030
3.4 North America Covid-19 Treatment Medicine 麻豆原创 Facts & Figures by Country
3.4.1 North America Covid-19 Treatment Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Covid-19 Treatment Medicine Sales by Country (2019-2030)
3.4.3 North America Covid-19 Treatment Medicine Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Covid-19 Treatment Medicine 麻豆原创 Facts & Figures by Country
3.5.1 Europe Covid-19 Treatment Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Covid-19 Treatment Medicine Sales by Country (2019-2030)
3.5.3 Europe Covid-19 Treatment Medicine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Covid-19 Treatment Medicine 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Covid-19 Treatment Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Covid-19 Treatment Medicine Sales by Country (2019-2030)
3.6.3 Asia Pacific Covid-19 Treatment Medicine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Covid-19 Treatment Medicine 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Covid-19 Treatment Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Covid-19 Treatment Medicine Sales by Country (2019-2030)
3.7.3 Latin America Covid-19 Treatment Medicine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Covid-19 Treatment Medicine 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Covid-19 Treatment Medicine 麻豆原创 Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Covid-19 Treatment Medicine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Covid-19 Treatment Medicine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Covid-19 Treatment Medicine Sales by Type (2019-2030)
4.1.1 Global Covid-19 Treatment Medicine Sales by Type (2019-2024)
4.1.2 Global Covid-19 Treatment Medicine Sales by Type (2025-2030)
4.1.3 Global Covid-19 Treatment Medicine Sales 麻豆原创 Share by Type (2019-2030)
4.2 Global Covid-19 Treatment Medicine Revenue by Type (2019-2030)
4.2.1 Global Covid-19 Treatment Medicine Revenue by Type (2019-2024)
4.2.2 Global Covid-19 Treatment Medicine Revenue by Type (2025-2030)
4.2.3 Global Covid-19 Treatment Medicine Revenue 麻豆原创 Share by Type (2019-2030)
4.3 Global Covid-19 Treatment Medicine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Covid-19 Treatment Medicine Sales by Application (2019-2030)
5.1.1 Global Covid-19 Treatment Medicine Sales by Application (2019-2024)
5.1.2 Global Covid-19 Treatment Medicine Sales by Application (2025-2030)
5.1.3 Global Covid-19 Treatment Medicine Sales 麻豆原创 Share by Application (2019-2030)
5.2 Global Covid-19 Treatment Medicine Revenue by Application (2019-2030)
5.2.1 Global Covid-19 Treatment Medicine Revenue by Application (2019-2024)
5.2.2 Global Covid-19 Treatment Medicine Revenue by Application (2025-2030)
5.2.3 Global Covid-19 Treatment Medicine Revenue 麻豆原创 Share by Application (2019-2030)
5.3 Global Covid-19 Treatment Medicine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer (Paxlovid)
6.1.1 Pfizer (Paxlovid) Corporation Information
6.1.2 Pfizer (Paxlovid) Description and Business Overview
6.1.3 Pfizer (Paxlovid) Covid-19 Treatment Medicine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer (Paxlovid) Covid-19 Treatment Medicine Product Portfolio
6.1.5 Pfizer (Paxlovid) Recent Developments/Updates
6.2 VEKLURY (Remdesivir)
6.2.1 VEKLURY (Remdesivir) Corporation Information
6.2.2 VEKLURY (Remdesivir) Description and Business Overview
6.2.3 VEKLURY (Remdesivir) Covid-19 Treatment Medicine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 VEKLURY (Remdesivir) Covid-19 Treatment Medicine Product Portfolio
6.2.5 VEKLURY (Remdesivir) Recent Developments/Updates
6.3 Lagevrio
6.3.1 Lagevrio Corporation Information
6.3.2 Lagevrio Description and Business Overview
6.3.3 Lagevrio Covid-19 Treatment Medicine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Lagevrio Covid-19 Treatment Medicine Product Portfolio
6.3.5 Lagevrio Recent Developments/Updates
6.4 GSK (Sotrovimab)
6.4.1 GSK (Sotrovimab) Corporation Information
6.4.2 GSK (Sotrovimab) Description and Business Overview
6.4.3 GSK (Sotrovimab) Covid-19 Treatment Medicine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GSK (Sotrovimab) Covid-19 Treatment Medicine Product Portfolio
6.4.5 GSK (Sotrovimab) Recent Developments/Updates
6.5 Regeneron (Ronapreve)
6.5.1 Regeneron (Ronapreve) Corporation Information
6.5.2 Regeneron (Ronapreve) Description and Business Overview
6.5.3 Regeneron (Ronapreve) Covid-19 Treatment Medicine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Regeneron (Ronapreve) Covid-19 Treatment Medicine Product Portfolio
6.5.5 Regeneron (Ronapreve) Recent Developments/Updates
6.6 Yiling Pharmaceutical
6.6.1 Yiling Pharmaceutical Corporation Information
6.6.2 Yiling Pharmaceutical Description and Business Overview
6.6.3 Yiling Pharmaceutical Covid-19 Treatment Medicine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Yiling Pharmaceutical Covid-19 Treatment Medicine Product Portfolio
6.6.5 Yiling Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Covid-19 Treatment Medicine Industry Chain Analysis
7.2 Covid-19 Treatment Medicine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Covid-19 Treatment Medicine Production Mode & Process
7.4 Covid-19 Treatment Medicine Sales and 麻豆原创ing
7.4.1 Covid-19 Treatment Medicine Sales Channels
7.4.2 Covid-19 Treatment Medicine Distributors
7.5 Covid-19 Treatment Medicine Customers
8 Covid-19 Treatment Medicine 麻豆原创 Dynamics
8.1 Covid-19 Treatment Medicine Industry Trends
8.2 Covid-19 Treatment Medicine 麻豆原创 Drivers
8.3 Covid-19 Treatment Medicine 麻豆原创 Challenges
8.4 Covid-19 Treatment Medicine 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Pfizer (Paxlovid)
VEKLURY (Remdesivir)
Lagevrio
GSK (Sotrovimab)
Regeneron (Ronapreve)
Yiling Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.